---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011164"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2022-06-03T23:59:59+00:00"
generated_at: "2026-06-25T04:56:24.932513+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sarepta shareholders approve 2.5M share increase to 2018 equity plan

## Summary
- Shareholders approved 2018 Plan Amendment, increasing authorized shares by 2.5M to 10,687,596.
- All four Class I director nominees elected: Boor, Chambers, Ingram, Wigzell.
- Advisory say-on-pay passed with 62,746,933 for (93.2% of votes cast).
- KPMG ratified as independent auditor for 2022 with 73,729,807 for.
- Equity plan vote: 62,644,364 for, 4,572,292 against, 55,530 abstain.

## SEC filing metadata
- accession: 0000950170-22-011164
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2022-06-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017022011164/0000950170-22-011164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017022011164/srpt-20220602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011164
- JSON: https://secwatch.observer/filing/0000950170-22-011164.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.